Zydelig idelalisib regulatory update

The European Commission approved an MAA from Gilead for Zydelig idelalisib to treat chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). Specifically, Zydelig is approved in combination with rituximab in adult CLL patients who have received >=1 prior therapy or as first-line treatment in the presence of 17p deletion or tumor protein p53 ( TP53; p53) mutation in patients unsuitable for chemo-immunotherapy; and as monotherapy in FL patients who are refractory to 2 prior lines of treatment. ...